CA2924682C - Utilisation de 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium ou d'un sel pharmaceutiquement acceptable de celui-ci dans la prevention et le traitement du diabete - Google Patents

Utilisation de 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium ou d'un sel pharmaceutiquement acceptable de celui-ci dans la prevention et le traitement du diabete Download PDF

Info

Publication number
CA2924682C
CA2924682C CA2924682A CA2924682A CA2924682C CA 2924682 C CA2924682 C CA 2924682C CA 2924682 A CA2924682 A CA 2924682A CA 2924682 A CA2924682 A CA 2924682A CA 2924682 C CA2924682 C CA 2924682C
Authority
CA
Canada
Prior art keywords
carboxy
aminium
dimethylpropan
ethyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2924682A
Other languages
English (en)
Other versions
CA2924682A1 (fr
Inventor
Maija Dambrova
Helena Cirule
Ivars Kalvins
Edgars Liepins
Elina MAKAROVA
Ilmars Stonans
Ilga Misane
Original Assignee
Grindeks JSC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grindeks JSC filed Critical Grindeks JSC
Publication of CA2924682A1 publication Critical patent/CA2924682A1/fr
Application granted granted Critical
Publication of CA2924682C publication Critical patent/CA2924682C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne l'utilisation de 3-carboxy-N-éthyl-N,N-diméthylpropan-1-aminium et de ses sels pharmaceutiquement acceptables pour diminuer les taux d'insuline et de glucose dans le plasma sanguin.
CA2924682A 2013-09-26 2014-09-15 Utilisation de 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium ou d'un sel pharmaceutiquement acceptable de celui-ci dans la prevention et le traitement du diabete Active CA2924682C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13186201.3 2013-09-26
EP13186201 2013-09-26
PCT/IB2014/064514 WO2015044828A1 (fr) 2013-09-26 2014-09-15 Utilisation de 3-carboxy-n-éthyl-n,n-diméthylpropan-1-aminium ou d'un sel pharmaceutiquement acceptable de celui-ci dans la prévention et le traitement du diabète

Publications (2)

Publication Number Publication Date
CA2924682A1 CA2924682A1 (fr) 2015-04-02
CA2924682C true CA2924682C (fr) 2018-02-27

Family

ID=49231372

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2924682A Active CA2924682C (fr) 2013-09-26 2014-09-15 Utilisation de 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium ou d'un sel pharmaceutiquement acceptable de celui-ci dans la prevention et le traitement du diabete

Country Status (9)

Country Link
CN (1) CN105530929B (fr)
AR (1) AR099638A1 (fr)
BR (1) BR112016004211B1 (fr)
CA (1) CA2924682C (fr)
JO (1) JO3333B1 (fr)
MX (1) MX368505B (fr)
TN (1) TN2016000064A1 (fr)
WO (1) WO2015044828A1 (fr)
ZA (1) ZA201600894B (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2067474A1 (fr) * 2007-12-05 2009-06-10 Grindeks, a joint stock company Nouvelle utilisation médicale de sel propionate 3-(2,2,2-trimethylhydrazinium)
LV14345B (lv) * 2009-10-22 2011-07-20 Grindeks, A/S 4-[Etil(dimetil)amonija]butanoāts un tā izmantošana kardiovaskulāro slimību ārstēšanai
BR112013027065B1 (pt) * 2011-04-27 2019-12-03 Grindeks Jsc processo para a preparação de sais de 3-carboxi-n-etil-n,n-dimetilpropan-1amínio, compostos e seus usos

Also Published As

Publication number Publication date
MX368505B (es) 2019-10-04
CN105530929A (zh) 2016-04-27
WO2015044828A1 (fr) 2015-04-02
ZA201600894B (en) 2017-05-31
JO3333B1 (ar) 2019-03-13
AR099638A1 (es) 2016-08-10
BR112016004211B1 (pt) 2022-09-06
CN105530929B (zh) 2018-03-02
CA2924682A1 (fr) 2015-04-02
BR112016004211A2 (fr) 2017-08-01
TN2016000064A1 (en) 2017-07-05
MX2016003347A (es) 2016-06-24

Similar Documents

Publication Publication Date Title
US20260102334A1 (en) Dopa decarboxylase inhibitor compositions
TWI405576B (zh) 疼痛疾病治療劑
US20250073193A1 (en) Dopa decarboxylase inhibitor compositions
JP6401317B2 (ja) がんを治療するためのシステム、方法、および製剤
TW200942231A (en) Synthetic triterpenoids and methods of use in the treatment of disease
US11337960B2 (en) Methods and compositions for the treatment of pre-diabetes, diabetes and metabolic syndrome
CA2924682C (fr) Utilisation de 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium ou d'un sel pharmaceutiquement acceptable de celui-ci dans la prevention et le traitement du diabete
CN102344950B (zh) 一种用于检测ssat底物的乙酰化代谢物的方法
EP3432874B1 (fr) Méthodes et compositions pour le traitement du syndrome de prader-willi
US7026338B2 (en) Pharmaceutical nitrones
US8927600B2 (en) Compound for use in the treatment of peripheral neuropathies
TWI472324B (zh) 應用二甲雙胍與丁酸鈉於ｋｒａｓ基因突變癌症治療之用途、醫藥組合物與醫藥套組
ES2359910T3 (es) Composición medicinal para inhibir la expresión de atp-citrato liasa y su uso.
EP3639818B1 (fr) Promoteur de consommation de glucose et promoteur de glycolyse
HK40043418B (en) Dopa decarboxylase inhibitor compositions
WO2020026570A1 (fr) Promoteur de consommation de glucose et promoteur de glycolyse
HK1058901A (en) Composition of biochemical compounds involved in bioenergy metabolism of cells and method of use

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160316

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240719

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240719

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250912

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250912